Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study.
Purpose: Antibodies against SARS-CoV-2 spike (anti-S) may confer protection against symptomatic COVID-19. Whether their level predicts progression among those with COVID-19 pneumonia remains unclear. Methods: We conducted a retrospective cohort study to assess predictors of anti-S levels and whether...
| Publicado en: | Infection Vol. 52; no. 4; pp. 1499 - 1510 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
Aug2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=178774663&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 178774663 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 03008126 NXO jtl: Infection issn: 03008126 maglogo: N pubinfo: dt: Aug2024 vid: 52 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 178774663 176779016 178774663 178774663 10.1007/s15010-024-02250-9 178774663 ppf: 1499 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study. aug: au: Lapadula, Giuseppe Mezzadri, Luca Lo Cascio, Giustina Antolini, Laura Malandrin, Sergio Ranzani, Alice Limonta, Silvia Cavallero, Annalisa Bonfanti, Paolo affil: Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy sug: subj: COVID-19 Immunology COVID-19 Mortality Antibodies, Viral Vaccination Status Disease Progression Risk Factors Hospitalization Pneumonia, Viral Immunology Risk Assessment Human Male Aged Aged, 80 and Over Retrospective Design Record Review Prospective Studies Sex Factors COVID-19 Vaccines Respiration, Artificial Logistic Regression Hematologic Neoplasms Immunosuppressive Agents Odds Ratio Confidence Intervals SARS-CoV-2 COVID-19 Prevention and Control Aged: 65+ years Aged, 80 & over Male ab: Purpose: Antibodies against SARS-CoV-2 spike (anti-S) may confer protection against symptomatic COVID-19. Whether their level predicts progression among those with COVID-19 pneumonia remains unclear. Methods: We conducted a retrospective cohort study to assess predictors of anti-S levels and whether anti-S titer is associated with death or mechanical ventilation (MV). Adults hospitalized for COVID-19 pneumonia between July 2021 and July 2022 were enrolled if anti-S had been measured within 72 h of admission. Predictors of anti-S level were explored using multivariable quantile regression. The association between anti-S levels and 30-day death/MV was investigated via multivariable logistic regression. Analyses were stratified by vaccine status. Results: The median anti-S level was 1370 BAU/ml in 328 vaccinated and 15.5 BAU/ml in 206 unvaccinated individuals. Among the vaccinated, shorter symptom duration (p = 0.001), hematological malignancies (p = 0.002), and immunosuppressive therapy (p = 0.004) were associated with lower anti-S levels. In the unvaccinated group, symptom duration was the only predictor of anti-S levels (p < 0.001). After 30 days, 134 patients experienced death or MV. Among vaccinated individuals, higher anti-S levels correlated significantly with lower death/MV risk (per log2 increase, OR 0.88, 95%CI 0.81–0.97), irrespective of age and solid malignancies. Among unvaccinated, a marginally protective effect was observed (OR 0.86, 95%CI 0.73–1.01), independent of age, immunosuppressive therapy, and diabetes. Adjustment for monoclonal antibody treatment strengthened the association (OR 0.81, 95%CI 0.68–0.96). Conclusion: This study suggests that levels of anti-S antibodies can predict critical or fatal outcomes in COVID-19 pneumonia patients, regardless of vaccination. Whether anti-S Ab could guide risk assessment and vaccination boosting merits further evaluation. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|